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Insulin resistance is a complex metabolic disorder that defies explanation by a single etiological
pathway. Accumulation of ectopic lipid metabolites, activation of the unfolded protein response
(UPR) pathway, and innate immunepathways have all been implicated in the pathogenesis of insulin
resistance. However, these pathways are also closely linked to changes in fatty acid uptake, lipo-
genesis, and energy expenditure that can impact ectopic lipid deposition. Ultimately, these cellular
changes may converge to promote the accumulation of specific lipid metabolites (diacylglycerols
and/or ceramides) in liver and skeletal muscle, a common final pathway leading to impaired insulin
signaling and insulin resistance.All metazoans are heterotrophic; they need to eat. This defining
characteristic poses a central challenge. Nutrient sources are
often scarce, and caloric demands constantly change. Animals
solved this problem by developing integrated mechanisms to
promote anabolism when calorie supply exceeds demands but
readily become catabolic when demands cannot be met with
consumption. The secretion and action of insulin (and related
molecules in lower phyla) provided one solution to this central
problem. Following nutrient consumption, insulin promotes
carbohydrate uptake at key storage sites and prompts the
conversion of carbohydrate and protein to lipids, a more efficient
storage for calories.
Although this ability to store dietary energy for later times has
supported the development of animal life for nearly 600 million
years, it has recently gone awry for humans. In a remarkably
short time, we have altered an environment of caloric scarcity
and high caloric demands into one with abundant caloric supply
with very little caloric demands. Obesity is now endemic, and
many societies are grappling with the rising prevalence of
obesity-associated diseases, including metabolic syndrome,
nonalcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D),
and atherosclerotic heart disease. These diseases exact tremen-
dous tolls on society through both the loss of health and quality
of life but also on health system resources. Insulin resistance is
sine quo non with the pathogenesis for many of these modern
diseases. Thus, understanding the pathogenesis of insulin resis-
tance has become increasingly important to guide the develop-
ment of future therapies and inform health and economic policy.
As stated above, insulin action essentially provides an inte-
grated set of signals that allow us to balance nutrient availability
and demands (Figure 1). There are diseases with impairments in
insulin production, as in type 1 diabetes or in the monogenic852 Cell 148, March 2, 2012 ª2012 Elsevier Inc.maturity onset diabetes of the young (MODY) syndromes. These
diseases are significant and can abruptly interrupt health, espe-
cially for children. In comparison, insulin resistance is insidious
and affects a far greater number of people. By some estimates,
within 40 years, one in every three Americans will have type 2
diabetes (Boyle et al., 2010).
Here, we review several mechanisms proposed to explain the
pathogenesis of insulin resistance—mainly, the development
of insulin resistance from ectopic lipid accumulation, the devel-
opment of ‘‘endoplasmic reticulum stress’’ and activation of
the unfolded protein response, and the contribution of systemic
inflammation. Though many additional mechanisms have been
offered, these three represent different aspects of metabolic
control that ultimately may converge on common pathways to
regulate insulin action.
Ectopic Lipid Accumulation
The association between lipids and insulin resistance is widely
accepted. Early studies byRandle and colleagues in rodent heart
and diaphragm muscle suggested that fatty acids impaired
insulin-mediated glucose uptake in muscle by inhibition of pyru-
vate dehydrogenase, leading to reductions in glucose oxidation
and accumulation of glycolytic intermediates (Randle et al.,
1963). In rats, acute (<2 hr) lipid infusions decreased myocellular
glucose utilization with the expected increases in intramyocellu-
lar glucose 6-phosphate (G-6-P) concentrations, as predicted
by Randle’s hypothesis (Jucker et al., 1997). Although this may
hold true for acute experimental challenges, it does not explain
insulin resistance in chronic disease states, which can be attrib-
uted to reductions in both insulin-stimulated muscle glycogen
synthesis and glucose oxidation (Shulman et al., 1990). Subse-
quent in vivo measurements of intramyocellular glucose and
Figure 1. Insulin Action
(Left) In the fed state, dietary carbohydrate (CHO)
increases plasma glucose and promotes insulin
secretion from the pancreatic b cells. Insulin has
numerous actions to promote storage of dietary
calories, but only some are illustrated here. In the
skeletal muscle, insulin increases glucose trans-
port, permitting glucose entry and glycogen
synthesis. In the liver, insulin promotes glycogen
synthesis and de novo lipogenesis while also in-
hibiting gluconeogenesis. In the adipose tissue,
insulin suppresses lipolysis and promotes lipo-
genesis.
(Right) In the fasted state, insulin secretion is
decreased. The drop in insulin (as well as the
action of other hormones that are not depicted)
serves to increase hepatic gluconeogenesis and
promote glycogenolysis. Hepatic lipid production
diminishes while adipose lipolysis increases.
(Bottom) In type 2 diabetes, ectopic lipid accu-
mulation impairs insulin signaling (as depicted by
the red ‘‘x’’). With accumulation of intramyocellular
lipid (IMCL), insulin-mediated skeletal muscle
glucose uptake is impaired. As a result, glucose is
diverted to the liver. In the liver, increased liver
lipid also impairs the ability of insulin to regulate
gluconeogenesis and activate glycogen synthesis.
In contrast, lipogenesis remains unaffected and,
together with the increase delivery of dietary
glucose, leads to increased lipogenesis and
worsening nonalcoholic fatty liver disease
(NAFLD). Impaired insulin action in the adipose
tissue allows for increased lipolysis, which will
promote re-esterification of lipids in other tissues
(such as liver) and further exacerbates insulin
resistance. Coupled with a decline in pancreatic
b cells (depicted by the smaller lines emanating
from the pancreas), hyperglycemia develops.
FA, fatty acids; TAG, triacylglycerol.G-6-P concentrations in a variety of rodent and human experi-
mental models have clearly demonstrated that lipid-induced
insulin resistance in skeletal muscle can be attributed to
impaired insulin signaling and decreased insulin-stimulated
glucose transport, and not to decreased glycolysis, as Randle
hypothesized (Cline et al., 1999; Dresner et al., 1999; Griffin
et al., 1999; Roden et al., 1996). In parallel, molecular studies
suggested that insulin resistance could be attributed to impaired
GLUT4 translocation, largely due to defects in insulin signaling
(Ciaraldi et al., 1995; Garvey et al., 1998) (Figure 1).
Lipids are clearly associated with insulin resistance. But, is it
the circulating plasma lipids or the lipids accumulating within
insulin responsive tissues that are responsible? Studies in
normal weight, nondiabetic adults found that intramyocellularCell 1triglyceride content is a far stronger
predictor of muscle insulin resistance
than circulating fatty acids (Krssak et al.,
1999), suggesting that intramyocellular
lipids may cause muscle insulin resis-
tance. This empiric observation has been
tested experimentally in normal rats
infused with Intralipid/heparin. Though
plasma fatty acids are acutely in-
creased, muscle insulin resistance didnot develop until 3–4 hr into the lipid infusion, concordant
with the accumulation of intramyocellular diacylglycerol (DAG)
and impairment in insulin signaling and muscle glucose
uptake. Of note, insulin resistance occurred independently
of changes in muscle triglyceride content, thus dissociating
muscle triglyceride concentrations from insulin resistance
(Dresner et al., 1999; Yu et al., 2002). Diacylglycerols are
signaling intermediates that activate members of the protein
kinase C (PKC) family. In these experiments, muscle lipid
accumulation is associated with activation of the novel PKC
(nPKC) isoform PKCq, providing a potential link between lipid
accumulation and alteration in intracellular signaling. This link
between DAG-mediated activation of nPKCs and muscle
insulin resistance has been replicated in human studies (Itani48, March 2, 2012 ª2012 Elsevier Inc. 853
Figure 2. Pathways Involved in Muscle Insulin Resistance
Insulin activates the insulin receptor (IR) tyrosine kinase, which subsequently tyrosine phosphorylates IRS1. Through a series of intermediary steps, this leads to
activation of Akt2. Akt2 activation, via AS160 and Rab-GTPase (not shown), promotes the translocation of GLUT4-containing storage vesicles (GSVs) to the
plasma membrane, permitting the entry of glucose into the cell, and promotes glycogen synthesis via glycogen synthase (GS). This central signaling pathway is
connected to multiple other cellular pathways that are designated by numbers 1–3.
(1) The green shaded areas represent mechanisms for lipid induced insulin resistance, notably diacylglycerol (DAG)-mediated activation of PKCq and subsequent
impairment of insulin signaling, as well as ceramide-mediated increases in PP2A and increased sequestration of Akt2 by PKCz. Impaired Akt2 activation limits
translocation of GSVs to the plasmamembrane, resulting in impaired glucose uptake. Impaired Akt2 activity also decreases insulin-mediated glycogen synthesis.
(2) The yellow areas depict several intracellular inflammatory pathways—notably, the activation of IKK, which may impact ceramide synthesis, and the activation
of JNK1, which may impair insulin signaling via serine phosphorylation of IRS1. (3) The pink area depicts activation of the unfolded protein response (UPR), which
under some instances (such as acute extreme exercise) may lead to activation of ATF6 and a PGC1a-mediated adaptive response. The endoplasmic reticulum
membranes also contain key lipogenic enzymes and give rise to lipid droplets. Proteins that regulate the release from these droplets (e.g., ATGL and PNPLA3)
may modulate the concentration of key lipid intermediates in discrete cell compartments.
CS, ceramide synthase; G3P, glycerol 3-phosphate; LPA, lysophosphatidic acid; SPT, serine palmitoyl transferase; TAG, triacylglycerol.et al., 2002; Szendroedi et al., 2011). Though both of these
studies have associated muscle diacylglycerol accumulation
with nPKC activation, there are some differences. Lipids
infused together with insulin over 6 hr result in activation of
PKCd (Itani et al., 2002). In contrast, PKCq activation
predominates when lipids were infused for 4 hr prior to
insulin infusion (Szendroedi et al., 2011). Together, these
studies support the paradigm that diacylglycerol accumula-
tion in muscle can lead to muscle insulin resistance through
activation of nPKCs (Figure 2).854 Cell 148, March 2, 2012 ª2012 Elsevier Inc.Ectopic lipid accumulation in the liver, termed nonalcoholic
fatty liver disease (NAFLD), is now considered themost common
chronic liver disease in the United States. By some estimates,
50% of Americans will have NAFLD by 2030 (Z.M. Younossi
et al., 2011, EASL, conference). However, many individuals
with NAFLD also have increased visceral adiposity, a marked
expansion of the omental fat. Though visceral adipose tissue
has been implicated as causing hepatic insulin resistance,
several studies present compelling data to the contrary. Patients
with severe lipodystrophy (Petersen et al., 2002) and a mouse
model of lipoatrophy (Kim et al., 2000) have no visceral fat but
manifest severe hepatic insulin resistance associated with
marked hepatic steatosis. In both, hepatic insulin resistance
resolves when the hepatic steatosis is reversed, either with fat
transplantation in mice (Kim et al., 2000) or recombinant leptin
therapy in humans with lipodystrophy. Though recombinant
leptin therapy works exquisitely well in patients with lipodystro-
phy, its application to a broader set of obese individuals has
not yielded similar results. But enforced dietary caloric restriction
can still rapidly reduce hepatic steatosis in obese patients
(Lim et al., 2011; Petersen et al., 2005). Subjects with poorly
controlled T2D who were placed on a hypocaloric diet for up to
12 weeks experienced a marked and rapid decrease in liver fat
content (85%), associated specifically with a normalization in
hepatic insulin sensitivity and reductions in fasting hypergly-
cemia and hepatic glucose production without changes in intra-
myocellular lipid or insulin-mediated whole-body glucose
disposal (Petersen et al., 2005). Consistent with these observa-
tions, Fabbrini et al. demonstrate that hepatic insulin resistance
is primarily related to intrahepatic lipid content, not visceral fat
mass (Fabbrini et al., 2009). And, they find that surgical removal
of visceral adipose tissue did not alter glucose homeostasis or
insulin sensitivity (Fabbrini et al., 2010). Taken together, these
studies demonstrate that ectopic lipid accumulation of lipid
within the liver can specifically cause hepatic insulin resistance.
Genetic rodent models that alter expression of lipid transport
proteins provide evidence for the role of ectopic lipid accumula-
tion in the pathogenesis of insulin resistance. Lipoprotein lipase
(LpL) is a key enzyme that hydrolyzes circulating triglyceride,
permitting tissue uptake through specific fatty acid transport
proteins (FATPs) together with CD36. Muscle-specific overex-
pression of lipoprotein lipase (LpL) promotesmuscle lipid uptake
and muscle insulin resistance (Kim et al., 2001). In contrast,
deletion of LpL (Wang et al., 2009) or of other proteins involved
in fat transport, such as CD36 (Goudriaan et al., 2003; Hajri
et al., 2002) or FATP1 (Kim et al., 2004b), protects mice from
muscle lipid accumulation and muscle insulin resistance when
challenged with high-fat diets (Figure 2). Similarly, hepatic
specific overexpression of LpL leads specifically to hepatic
steatosis and hepatic insulin resistance (Kim et al., 2001; Merkel
et al., 1998). Adenoviral-mediated overexpression of hepatic
CD36 causes NAFLD, even in regular chow-fed mice (Koonen
et al., 2007). Loss of hepatic fatty acid transport, specifically
through deletion of FATP2 (Falcon et al., 2010) or FATP5 (Doege
et al., 2008), protects against the development of hepatic steato-
sis and glucose intolerance (Figure 3).
The liver also actively exports lipids. The importance of this
balance between hepatic lipid uptake and export is demon-
strated in mice that overexpress human apolipoprotein CIII
(ApoC3). ApoC3 can inhibit LpL activity and limit peripheral fat
uptake, thereby promoting postprandial hyperlipidemia. Though
transgenic mice that overexpress ApoC3 (ApoC3 tg) have
marked hypertriglyceridemia, hepatic lipid content in regular
chow-fed mice is not different than wild-type mice fed the
same diet (Lee et al., 2011b). However, when placed on
a high-fat diet, ApoC3 tg mice develop hepatic steatosis
with diacylglycerol accumulation, PKCε activation, and hepatic
insulin resistance (Lee et al., 2011b). The development ofhepatic steatosis could be attributed to a mismatch between
hepatic lipid uptake and lipid export in the high fat-fed
mice; hepatic lipid uptake is increased under both conditions,
but export, via ApoB100 containing VLDL particles, is decreased
in the hyperinsulinemic fat-fed mice due to suppression of
ApoB100 expression. This has relevance to human disease.
Lean individuals (body mass index < 25 kg/m2) who carry poly-
morphisms in the insulin response element of the ApoC3 gene
(rs2854116 and rs2854117) have increased fasting plasma
ApoC3 concentrations and fasting hypertriglyceridemia (Pe-
tersen et al., 2010). This is associated with a decrease in plasma
lipid clearance after both an oral and intravenous lipid challenge
and an increase in hepatic steatosis. Thus, as with the ApoC3 tg
mice, when individuals carrying polymorphisms in ApoC3 exist in
‘‘toxic environments’’ (Novak and Brownell, 2011), they are
prone to NAFLD and hepatic insulin resistance. Importantly,
this subtle gene-environment relationship is not evident in obese
subjects who already have a high prevalence of NAFLD (Kozlitina
et al., 2011). Thus, ectopic lipid accumulation in liver either from
increased delivery or decreased export can lead to hepatic
insulin resistance. Though genetic defects in hepatic mitochon-
drial fatty acid oxidation (e.g., mice lacking long-chain acyl-CoA
dehydrogenase [LCAD]) can also be a predisposing condition to
hepatic steatosis and hepatic insulin resistance (Zhang et al.,
2007), studies in patients with NAFLD are few and differ in their
conclusions, with some studies reporting reduced (Cortez-Pinto
et al., 1999; Schmid et al., 2011) and others reporting increased
hepatic mitochondrial metabolism (Sunny et al., 2011).
Lipid Mediators of Insulin Resistance
Lipids, as signaling intermediates, encompass a vast range of
molecules with distinct functions. Though circulating lipids
(e.g., endotoxins and prostaglandins) were the earliest recog-
nized lipid signals, intracellular lipid intermediates (such as diac-
ylglycerols, ceramides, and PIP3) also mediate intracellular
signaling. The local production of these lipid metabolites has
been thought to provide some degree of signaling localization.
That is, signaling events and therefore cellular actions can be
directed to specific regions within the cell in response to the
generation of a key lipid intermediate. So, what is the patholog-
ical lipid moiety that triggers insulin resistance? Upon cellular
entry, fatty acids are rapidly esterified with coenzyme A to fatty
acyl-CoAs. These are successively transferred to a glycerol
backbone to form mono-, di-, and triacylglycerols. They can
also esterify with sphingosine to form ceramides. Some of these
lipid intermediates (e.g., diacylglycerol and ceramides) are also
known to function as second messengers in key signaling path-
ways. These lipid intermediates comprise a lineup of metabolic
suspects implicated in the pathogenesis insulin resistance.
These associations can be directly tested using genetic mouse
models that modulate the expression of the enzymes involved
in lipid metabolism.
Mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltrans-
ferase (mtGPAT) catalyzes the formation of lysophosphatidic
acid from fatty acyl CoA and glycerol 3-phosphate (Figure 3).
When mtGPAT-deficient (mtGPAT1/) mice are placed on a
high-fat diet, they accumulate hepatic fatty acyl-CoA, but not
hepatic diacylglycerol and triglyceride (Neschen et al., 2005).Cell 148, March 2, 2012 ª2012 Elsevier Inc. 855
Figure 3. Pathways Involved in Hepatic Insulin Resistance
Insulin activates the insulin receptor (IR) tyrosine kinase, which subsequently tyrosine phosphorylates IRS1 and 2. Through a set of intermediary steps, this leads
to activation of Akt2. Akt2 can promote glycogen synthesis (not shown), suppress gluconeogenesis, and activate de novo lipogenesis (DNL). This central signaling
pathway is connected to multiple other cellular pathways that are designated by numbers 1–3. Key lipid synthesis pathways are juxtaposed within this domain
and are regulated by them.
(1) The green shaded areas represent mechanisms for lipid-induced insulin resistance—notably, diacylglycerol-mediated activation of PKCε and subsequent
impairment of insulin signaling, as well as ceramide mediated increases in PP2A and increased sequestration of Akt2 by PKCz. Impaired Akt2 activation limits the
inactivation of FOXO1 and allows for increased expression of key gluconeogenesis enzymes. Impaired Akt2 activity also decreases insulin-mediated glycogen
synthesis (not shown). (2) The yellow areas depict several intracellular inflammatory pathways—notably, the activation of IKK, which may impact ceramide
synthesis, and the activation of JNK1, which may impair lipogenesis. (3) The pink area depicts activation of the UPR that can lead to increased lipogenesis via
XBP1s and also increased gluconeogenesis via C/EBP. The ER membranes also contain key lipogenic enzymes and give rise to lipid droplets. Proteins that
regulate the release from these droplets (e.g., ATGL and PNPLA3) may modulate the concentration of key lipid intermediates in discrete cell compartments.
CS, ceramide synthase; DNL, de novo lipogenesis; FA-CoA, fatty acyl CoA; G3P, glycerol 3-phosphate; LPA, lysophosphatidic acid; SPT, serine palmitoyl
transferase; TAG, triacylglycerol; TCA, tricarboxylic acid cycle; PEP, phosphoenolpyruvate.Despite the 2-fold increase in fatty acyl-CoA,mtGPAT1-deficient
mice are protected from diet-induced hepatic insulin resistance.
Though hepatic mtGPAT overexpression does not decrease
fatty acyl-Coa, it still leads to hepatic insulin resistance that is
associated with increased lysophosphatidic acid, DAG, and
TAG (Nagle et al., 2007). Together, these studies suggest that
fatty acyl CoAs do not cause insulin resistance.
Several lines of evidence support a role for ceramides in the
pathogenesis of insulin resistance. Ceramides are primarily856 Cell 148, March 2, 2012 ª2012 Elsevier Inc.membrane lipids, a precursor in the formation of sphingomyelin.
However, increases in hepatic and muscle ceramide content,
along with diacylglycerols, have been associated with insulin
resistance in obese Zucker (fa/fa rats, homozygous for a trun-
cated, nonfunctional leptin receptor) (Turinsky et al., 1990).
Treating fat-fed mice with myriocin, an inhibitor of serine palmi-
toyl transferase 1, specifically attenuates the increase in muscle
ceramide content in fat-fed mice without any change in long-
chain acyl-CoAs, diacylglycerols, or triglyceride and improves
glucose tolerance. The role of ceramides as a mediator of insulin
resistance may be limited to saturated fats. Myriocin prevents
acute skeletal muscle insulin resistance following infusion of
palmitate, but not oleate (Holland et al., 2007).Mice fed 12weeks
of a lard-based diet (60% fat calories) are protected from
glucose intolerance when treated with myriocin (Ussher et al.,
2010). Inflammatory signals may link saturated fatty acids to
ceramide synthesis. Palmitate infusion increases plasma
cytokine concentrations, and mice lacking Toll-like receptor 4
(TLR4) are protected from ceramide accumulation and insulin
resistance following lard, but not soy oil, infusions (Holland
et al., 2011). Some have also suggested that saturated fatty
acids may also be the ligands for TLR4 (Shi et al., 2006). Thus,
intracellular ceramides may also act as ‘‘second messengers’’
that coordinate a cell’s response to circulating cytokines or
possibly nutrient (e.g., saturated fatty acids) signals.
In some instances, diacylglycerols also function as second
messengers (specifically sn1,2 diacylglycerol) canonically pro-
duced from phosphatidylinositol 4,5-bisphosphate by the action
of phospholipase C. In contrast, with ectopic lipid accumulation
in insulin resistant states, intracellular diacylglycerol accumula-
tion can be secondary to a mismatch in the rate of diacylglycerol
synthesis exceeding the rate of its incorporation into triacyl-
glyerol or triglyceride hydrolysis pathways. Thus, diacylglycerols
are metabolites that also have intracellular signaling properties.
This association between diacylglycerol and insulin resistance
can be illustrated in mice with genetic manipulations of the
Acyl-CoA:diacylglycerol acyltransferase (DGAT), the enzymes
that acylate diacylglycerols into triglycerides. Mice that overex-
press skeletal muscle DGAT1 (MCK-DGAT1) accumulatemuscle
triglyceride but are protected from lipid-induced muscle insulin
resistance (Liu et al., 2007) and recapitulate the athlete’s
paradox in which endurance athletes have increased muscle
triglyceride yet are insulin sensitive (Goodpaster et al., 2001;
Krssak et al., 2000). Though muscle triglyceride content is
increased in the MCK-DGAT1 mice, muscle DAG content is
lower and may account for the protection from lipid-induced
insulin resistance. DAGs can also be converted into phospha-
tidic acid, a major membrane lipid, by diacylglycerol kinases
(DGKs) (Chibalin et al., 2008). DGKd expression is decreased in
skeletal muscles of both hyperglycemic rodents and poorly
controlled diabetic patients. In mice, DGKd haploinsufficiency
(DGKd+/) increases muscle DAG, but not triglyceride, and
results specifically in muscle insulin resistance. Taken together
with the previous studies on GPAT, these studies exonerate
tissue fatty acyl CoA and triglyceride as pathogenic lipid species
for insulin resistance.
Other genetic studies of the DGAT enzyme family reveal a
complicated relationship between DGAT, its substrates, and its
product. Considering the results in the MCK-DGAT1 mice, dele-
tion of DGAT1 should specifically promote DAG, but not triglyc-
eride, accumulation and lead to insulin resistance. In actuality,
DGAT1 knockoutmice have reductions in both tissue triglyceride
and diacylglycerol content (Smith et al., 2000) and are resistant
to diet-induced obesity and insulin resistance. DGAT2, which
is normally highly expressed in white adipose and liver, is
thought to be a more potent diacylglycerol acyltransferase.
Transgenic overexpression of DGAT2 in glycolytic fibers (MCK-DGAT2) promotes increases in muscle triglyceride content and
decreases in muscle diacylglycerol content, as expected, but
surprisingly also increases muscle fatty acyl CoAs and ceramide
content (Levin et al., 2007). MCK-DGAT2 mice develop modest
muscle insulin resistance and suggest that other lipid metabo-
lites (e.g., ceramides) may also mediate the development of
insulin resistance. In contrast, transgenic overexpression of
hepatic DGAT2 increases hepatic triacylglycerol (TAG) and
DAG content 3-fold and hepatic ceramide content by 10%
and is associated with hepatic insulin resistance (Jornayvaz
et al., 2011). Decreasing hepatic and adipose DGAT2 expression
with specific antisense oligonucleotides (ASOs) lowers diacyl-
glycerol content by inhibiting lipogenesis and reverses diet-
induced hepatic insulin resistance (Choi et al., 2007). These
studies demonstrate a sometimes paradoxical effect of DGAT
modulation on hepatic diacylglycerol content. Overexpression
can at times increase lipid intermediates that are proximal to
DGAT (as in muscle and liver DGAT2 transgenics), whereas inhi-
bition can decrease these proximal metabolites. In the latter
case, it is possible that transient increases in early lipid interme-
diates (e.g., fatty acyl CoAs) may serve to suppress the lipogenic
pathway (Choi et al., 2007). Though the underlying cellular
mechanisms accounting for lipid changes may be counterintui-
tive, the results from these studies support the association
between insulin resistance and the accumulation of both diacyl-
glycerols and ceramides.
Intracellular Lipid Localization and Insulin Resistance
Most studies relating ectopic lipid accumulation to insulin resis-
tance focus on the total lipid content within key tissues. But does
the intracellular localization of lipid species matter in relation to
insulin resistance? Lipids are, after all, pervasive cell constitu-
ents, present in all membranes and in lipid droplets and esterified
to various carriers (e.g., coenzyme A and carnitine). Does the
lipid content in different intracellular compartments affect the
development of insulin resistance? A definitive answer is not
available, but some recent studies suggest that subcellular local-
ization does matter with regards to insulin resistance.
Intracellular lipid droplets, or ‘‘adiposomes,’’ (Liu et al., 2004)
are now considered sites of active lipid synthesis and lipolysis
(Figures 2 and 3). They possess a mantle of enzymes that
regulate the entry and exit of lipid species. In rare instances,
mutations in some lipid droplet proteins are associated with
congenital lipodystrophy syndromes. Recently, genome-wide
array screens have associated NAFLD with a relatively common
single-nucleotide polymorphism, rs738409, in the gene encod-
ing the lipid droplet protein patatin-like phospholipase domain-
containing protein 3 (PNLPA3) (Romeo et al., 2008). This protein,
also called adiponutrin, possesses both triglyceride lipase
and transacylation activity (Jenkins et al., 2004). The rs738409
polymorphism causes a I148M substitution in the protein that
results in a loss of lipolytic activity. Although carriers of this
single-nucleotide polymorphism (SNP) have increased liver fat
content, most reports suggest that it is not associated with
insulin resistance (Kantartzis et al., 2009; Kotronen et al., 2009;
Speliotes et al., 2010). A recent study demonstrates that even
children with this polymorphism have higher liver triglyceride
but without any change in hepatic insulin sensitivity relative toCell 148, March 2, 2012 ª2012 Elsevier Inc. 857
control subjects (Santoro et al., 2010). Although these data pose
a compelling challenge to the notion that ectopic lipid accumula-
tion causes insulin resistance, the subjects in many of these
studies were already obese, and even the control subjects
were relatively insulin resistant. Thus, to truly discern whether
PNPLA3 confers a risk of steatosis without additional insulin
resistance, hepatic insulin sensitivity will need to be assessed
between lean PNPLA3 wild-type individuals with NAFLD and
lean PNPLA3 variant carriers with NAFLD.
Rodent studies exploring the function of PNPLA3 have so far
not helped to resolve this quandary. Adenoviral overexpression
of the mutant gene in mice increases lipid droplet size and
triglyceride accumulation in vivo, consistent with the human
data (He et al., 2010). And there is consensus that PNPLA3
expression is regulated by SREBP1c and perhaps by ChREBP
(Dubuquoy et al., 2011; Huang et al., 2010; Qiao et al., 2011).
However, the exact role of PNPLA3 in regulating lipid metabo-
lism remains unknown. A priori, if PNPLA3 functions as a lipase,
increased hepatic PNPLA3 expression should promote lipolysis
and decrease liver lipid content. However, overexpression of the
wild-type PNPLA3 does not alter liver lipid content (He et al.,
2010; Qiao et al., 2011). In addition, PNPLA3 knockout mice
do not develop hepatic steatosis and do not appear to have
altered glucose homeostasis, even when provoked with a variety
of dietary challenges (Basantani et al., 2011; Chen et al., 2010).
This putative lipase also possesses transacylation activity and
thus may also have a role in lipid synthesis (Jenkins et al.,
2004). PNPLA3 expression in adipose tissue (Caimari et al.,
2007; Kershaw et al., 2006) and liver (Huang et al., 2010)
decreases with fasting and increases in response to insulin
and glucose—the opposite of what would be expected from
a triglyceride lipase and more consistent with a potential role in
lipogenesis. Additional studies are needed to better understand
the role of PNPLA3 in regulating lipid homeostasis, specifically
how polymorphisms may affect its transacylase and lipolytic
function and whether this alters the accumulation of key
signaling lipid metabolites, e.g., diacylglycerol or ceramides.
In contrast, adipose triglyceride lipase (ATGL, also known as
desnutrin and PNPLA2) is a potent lipase that catalyzes the
hydrolysis of triglycerides into diacylglycerols. Mice lacking
ATGL have marked alterations in lipid metabolism with ectopic
lipid accumulation in most tissues, manifesting dramatically
with massive cardiac lipid accumulation leading to premature
death (Haemmerle et al., 2006). Despite adiposity and ectopic
lipid accumulation, glucose tolerance is improved, again excul-
pating triglycerides in the pathogenesis of insulin resistance.
Recent studies in humans have found that ATGL protein expres-
sion in skeletal muscle is inversely related to whole-body insulin-
stimulated glucose disposal in humans (Badin et al., 2011). A
possible mechanistic link is proposed from in vitro experiments.
Overexpression of ATGL in cultured myotubules increases both
diacylglycerol and ceramide content and is associated with
impaired insulin signaling. The nonselective PKC inhibitor cal-
phostin-C prevents this impairment in insulin signaling, suggest-
ing that PKC activation is required for ATGL-mediated insulin
resistance (Badin et al., 2011).
ATLG exerts profound influence over whole-body energy
metabolism. ATGL-deficient mice have impaired thermogenesis858 Cell 148, March 2, 2012 ª2012 Elsevier Inc.when exposed to cold (Haemmerle et al., 2006). These mice are
more reliant on carbohydrate oxidation during the light phase
(fasting) of the diurnal cycle and, when subjected to exercise,
have a greater depletion ofmuscle and liver glycogen, consistent
with an inability to switch to a lipid fuel source (Huijsman et al.,
2009). Additional insights are gleaned from tissue-specific
modulation of ATGL expression. Adipose-specific deletion of
ATGL recapitulates some of the phenotype of the whole-body
knockout, with decreased energy expenditure and thermogene-
sis. Yet, this still prevents diet-induced insulin resistance attrib-
utable to a decrease in liver diacylglycerol content (Ahmadian
et al., 2011). Surprisingly, adipose-specific overexpression of
ATGL also appears to protect mice from insulin resistance.
This phenotype is thought to be due to an increase in futile lipid
cycling and increased white adipose tissue UCP1 expression,
which increases energy expenditure (Ahmadian et al., 2009).
Liver-specific deletion of ATGL renders mice to be more prone
to hepatic steatosis and decreased lipid oxidation but without
alteration in glucose tolerance (Wu et al., 2011). In comparison,
adenoviral overexpression of hepatic ATGL reduces liver lipids
(including DAGs and ceramides), possibly due to decreased
lipogenesis and increased lipid oxidation, and is associated
with increased insulin sensitivity during an insulin tolerance test
(Turpin et al., 2011). Together, these studies suggest a role for
ATGL both in regulating energy balance and in the generation
of key lipid intermediates. Without ATGL, cells cannot readily
access the energy stored in triglycerides but also cannot
generate the lipid mediators of insulin resistance. In contrast,
forced overexpression may trigger an imbalance between
synthesis and storage, establishing futile cycles that waste
energy.
ATGL is a tightly regulated enzyme through both modification
(e.g., phosphorylationbyAMPK[Ahmadianetal., 2011]) and regu-
latory proteins. ATGL is activatedby comparative gene identifica-
tion-58 (CGI-58) protein and pigment epithelial-derived factor
(PEDF) and is inhibited by the G0/G1 switch gene 2 (G0S2). Anti-
sense oligonucleotide-mediated knockdown of the CGI-58
protein, a key activator of ATGL, markedly increases hepatic
TAG, DAG, and ceramide in fat-fed mice (Brown et al., 2010).
Despite the increases in these lipid species, knockdown of CGI-
58 is associated with improved glucose tolerance and insulin
sensitivity. These studies also challenge the association between
ectopic lipidaccumulationand insulin resistanceandsuggest that
additional levels of control are present. ATGL can also be acti-
vated by the pigment epithelial-derived factor (PEDF) (Chung
et al., 2008). Five days of exogenous PEDF administration mark-
edly decreasesmuscle triglyceride content, though not diacylgly-
cerol or ceramide content (Borg et al., 2011). Insulin tolerance
tests performed under these conditions revealed a more rapid
recovery of blood glucose after insulin in wild-type mice treated
with PEDF, but not ATGL/mice, suggesting that the effects of
PEDF are ATGL dependent. In contrast to CGI-58 and PEDF,
G0S2 inhibits ATGL activity (Yang et al., 2010b). Though expres-
sion of G0S2 can inhibit lipolysis, there are no data on how it may
modulate insulin sensitivity—specifically, whether it could
improve insulin sensitivity, as in genetic deletions of ATGL.
Recently, studies in mice that overexpressed DGAT2 have
suggested that the intracellular localization of diacylglycerol is
important (Jornayvaz et al., 2011). This enzyme is localized to the
endoplasmic reticulum but, with lipid accumulation, is highly
expressed in the lipid droplet membranes (Stone et al., 2009).
Mice overexpressing hepatic DGAT2 develop hepatic steatosis
(Monetti et al., 2007) associated with hepatic, but not peripheral,
insulin resistance (Jornayvaz et al., 2011). Whereas total DAG
content is only modestly increased in the DGAT2 transgenic
mice (specifically the ‘‘low-overexpressing’’ strain), the DAG
content in the cytosolic fraction containing the lipid droplets is
increased nearly 10-fold and associated with activation of
PKCε, impairment of insulin signaling, and hepatic insulin resis-
tance. Though preliminary, these data, together with our growing
understanding of the biology of lipid droplets suggest that traf-
ficking of lipids between intracellular compartments may play
a key role in the development of insulin resistance.
From Lipid Accumulation to Insulin Resistance
Diacylglycerol and Novel Protein Kinase Cs
Protein kinase C family members are ideal for sensing a lipid
signal and, through kinase activity, affecting cellular events in
response. The PKC kinases belong to a larger family of AGC
kinase that includes a broad array of serine/threonine kinases
and are themselves further subdivided into three categories:
conventional PKCs (cPKC: a, bI, bII, and g) that require both
calcium and diacylglycerol for activation, novel PKCs (nPKC: d,
ε, h, and q) that require only diacylglycerol, and atypical PKCs
(aPKC: z and l) that require neither calcium nor diacylglycerol.
Of interest, sequence analyses suggest that the atypical PKCs
may, in fact, be the most ancient, suggesting that, as biological
systems became more complex, PKCs evolved into additional
signaling roles (Miyake et al., 2009).
Earlier studies demonstrated that activation of PKCs with
phorbol acetate cause insulin resistance (Ha¨ring et al., 1986;
Jacobs et al., 1983; Karasik et al., 1990) and that PKCs are acti-
vated in diabetic rodent models (Avignon et al., 1996; Considine
et al., 1995). In rodents, an infusion of Intralipid/heparin to raise
plasma fatty acid concentrations leads to skeletal muscle insulin
resistance attributed to impaired insulin signaling and associ-
ated with activation of PKC-q (Griffin et al., 1999). The develop-
ment of insulin resistance with intralipid infusion is associated
with an increase in muscle diacylglycerol content but indepen-
dent of changes in ceramide and triglyceride content (Yu et al.,
2002). Mice lacking PKCq are protected from skeletal muscle
insulin resistance under a similar acute lipid infusion (Kim et al.,
2004a). In contrast, following 14 weeks of high-fat feeding,
PKCq knockout mouse are prone to diet-induced obesity and,
in this setting, develop muscle, adipose, and hepatic insulin
resistance (Gao et al., 2007). PKCq knockout mice have
decreased locomotor activity and energy expenditure. Thus,
though lack of PKCq may protect from acute lipid-induced
muscle insulin resistance, a chronic high-fat diet can still lead
to insulin resistance, either due to the development of hepatic
insulin resistance or the activation of other nPKC isoforms in
skeletal muscle.
PKCs are also implicated in the pathogenesis hepatic insulin
resistance in NAFLD. In rodents, 3 days of high-fat feeding cause
marked hepatic steatosis and hepatic insulin resistance without
peripheral adiposity muscle lipid accumulation and peripheralinsulin resistance. In this setting, hepatic insulin resistance is
associated specifically with activation of PKCε. Decreasing
PKCε expression using a specific ASO enhances hepatic insulin
response in fat-fed rats despite hepatic steatosis, demonstrating
that PKCε is required for the development of hepatic insulin
resistance in NAFLD. Consistent with these findings, PKCε
knockout mice (Prkce/) are protected from diet-induced
insulin resistance following 1 week of high-fat feeding (Raddatz
et al., 2011) despite subtle increases in liver lipid content. Inter-
estingly, Prkce/ were prone to hepatic steatosis with chronic
(16 weeks) high-fat feeding. Despite this, Prkce/mice
continued to display enhanced glucose tolerance, though at
this time point, this finding was attributed to increased insulin
secretion.
PKCd is another novel isoform that is also associated with
hepatic insulin resistance. PKCd is activated in the livers of rats
subjected to a 6 hr Intralipid/heparin infusion, concomitant with
the development of hepatic insulin resistance (Lam et al.,
2002). During a lipid infusion, PKCd activation occurs simulta-
neously with activation of IKK-b, raising the possibility that
PKCd may also be responding to a proinflammatory milieu that
develops with persistent hyperlipidemia (Boden et al., 2005).
Recently, studies have suggested that PKCd may play a role in
lipid balance in rodents and humans. Either whole-body or
liver-specific loss of PKCd decreases liver lipids (whole-body
knockout mice were also lighter) and improves glucose toler-
ance, whereas adenoviral-mediated overexpression promotes
hepatic steatosis and worsens glucose tolerance (Bezy et al.,
2011; Frangioudakis et al., 2009). The effects of PKCd may be
mediated through altered lipogenesis; expression of key lipo-
genic enzymes is decreased in PKCd knockout mice and
increases following adenoviral overexpression. Hepatic PKCd
mRNA expression is related to higher plasma triglyceride and
glucose concentration in humans as well (Bezy et al., 2011). It
is possible that its association with insulin resistance ultimately
may reflect its ability to regulate ectopic lipid accumulation.
Thus, although PKCd is important for the development of hepatic
steatosis, the exact role, either as part of an inflammatory signal
or a mediator of lipid homeostasis, remains to be defined
(Figure 3).
How exactly do nPKCs impair insulin signaling? Early studies
using phorbol acetates as a PKC activator suggested that
PKCs interfere with insulin receptor activation (Anderson and
Olefsky, 1991; Pillay et al., 1990; Takayama et al., 1988). Though
putative PKC phosphorylation sites had been identified on the
insulin receptor (Coghlan et al., 1994; Lewis et al., 1990), subse-
quent studies using phosphospecific antibodies failed to identify
insulin receptor phosphorylation at these sites in skeletal muscle
biopsies obtained from diabetic patients (Kellerer et al., 1995).
Yu et al. found that PKCq activation associated with decreased
insulin-stimulated IRS-1 tyrosine phosphorylation was associ-
ated with increased IRS-1 serine phosphorylation, and recent
studies have shown that PKCq can phosphorylate IRS-1 on
Ser 1101, which has been shown to block insulin-stimulated
IRS-1 tyrosine phosphorylation (Li et al., 2004). Recent studies
have also found that nPKC-mediated impairment of insulin
receptor kinase activity may occur in the liver. In rat liver, PKCε
and the insulin receptor are closely associated with each other.Cell 148, March 2, 2012 ª2012 Elsevier Inc. 859
Moreover, ASO-mediated inhibition of PKCε expression
prevents high-fat diet-induced impairments in insulin receptor
kinase activation. Together, these data provide a paradigm to
explain insulin resistance in both muscle and liver with lipid
excess—namely, that diacylglycerol-mediated activation of
nPKCs directly impairs insulin signaling and insulin action.
Ceramides and Akt2
In several of the models discussed previously, the development
of insulin resistance is associated with tissue accumulation of
ceramide species as well as diacylglycerol, though increases
in ceramides may be specific to particular types of lipid chal-
lenges (e.g., palmitic acid, but not oleic acid). Accumulation of
ceramides has been associated with impaired Akt2 action. This
appears to be due to a direct effect on Akt2 activation and not
impairments in upstream signaling events (e.g., IR kinase activa-
tion or PI3 kinase activation) (Schmitz-Peiffer et al., 1999;
Stratford et al., 2004). There are several proposed mechanisms
whereby ceramides may impair Akt2 activation. First, ceramides
may lead to activation of protein phosphatase 2A (Teruel et al.,
2001), which can dephosphorylate Akt2, effectively dampening
insulin signaling (Figure 3). In addition, ceramides may impair
insulin action via the atypical PKC isoform, PKCz (Powell et al.,
2003). PKCz and Akt2 interact intracellularly but dissociate
upon insulin stimulation; ceramides impair this disassociation,
and furthermore, via PKCz phosphorylation of Akt2, prevent
Akt2 activation (Figure 3). Ceramides may accumulate in
caveolin-enriched microdomains (Fox et al., 2007) and recruit
PKCz, which in turn could sequester Akt2 and prevent it from
participating in insulin signaling (Blouin et al., 2010). To date,
these cellular mechanisms have largely been studied using cell
systems, and future studies are required to translate these
in vitro findings to in vivo models of insulin resistance and
humans.
Lipids and the Unfolded Protein Response
A second broad theme for the pathogenesis of insulin resistance,
particularly for hepatic insulin resistance with NAFLD, is the
activation of the unfolded protein response (UPR), also termed
endoplasmic reticulum stress. The UPR is initiated with the
accumulation of unfolded proteins with the ER lumen. Exposure
of hydrophobic b sheets, which should comprise the core of
a folded protein, avidly recruit glucose-regulated protein 78
(GRP78, also termed BiP or immunoglobulin-binding protein)
away from the key UPR effectors allowing activation. Activation
of three canonical arms, inositol requiring enzyme-1 (IRE1a),
PKR-like ER kinase (PERK), and activating transcription factor-
6 (ATF6), work to reduce unfolded proteins with the ER lumen
by increasing membrane biogenesis (specifically via the IRE1
arm), halting protein translation (via the PERK arm), and
enhancing expression of ER chaperones (Okada et al., 2002).
Activation of the UPR was observed in the livers of leptin-
deficient ob/ob mice (Ozcan et al., 2004), suggesting that these
pathways may be involved in the pathogenesis of insulin resis-
tance in obese states in rodents as well as in humans (Gregor
et al., 2009). Chemical inducers of the UPR impaired insulin
signaling (Ozcan et al., 2004), whereas chemical chaperones
that reduce ER stress improved insulin signaling (Ozcan et al.,
2006). Further, markers of the UPR are decreased after surgical860 Cell 148, March 2, 2012 ª2012 Elsevier Inc.induced weight loss (Gregor et al., 2009). Though the UPR is
clearly associated with insulin resistance, there are critical
gaps in our understanding of this relationship.
In many instances, activation of the UPR provides cells the
ability to adapt to changing demands. In insulin-resistant states,
beneficial adaption is seen in pancreatic b cells. The increased
requirements for insulin production could overwhelm the
capacity of the ER to process and secrete insulin. Inhibition of
the UPR could lead to b cell dysfunction, as is seen in b cell-
specific XBP1 knockout mice (Lee et al., 2011a). However, in
other tissues, such as liver and adipose, activation of the UPR
is thought maladaptive; in the prevailing view, IRE1-mediated
activation of the Jun-N-terminal kinase 1 (JNK1, also known as
mitogen-activated protein kinase-8 [MAPK8]) leads to serine
phosphorylation of insulin receptor substrate-1 at a key serine
(307), which is thought to lead to impaired insulin signaling
(Ozcan et al., 2004; Tuncman et al., 2006). Though compelling,
several critical questions remain unanswered regarding this
paradigm.
The UPR in NAFLD and Hepatic Insulin Resistance
A significant amount of work has focused on the role of UPR in
the pathogenesis of hepatic insulin resistance and NAFLD
(Figure 3). The UPR regulates lipogenesis, allowing for expansion
of the ER membrane and increasing the capacity of the ER to
handle proteins. This can be demonstrated even in wild-type
mice, in which chemical activators of the UPR can lead to a tran-
sient hepatic steatosis. Genetic mouse models have provided
additional insights into the mechanisms whereby the UPR may
regulate lipogenesis. Overexpression of GRP78 can suppress
activation of the UPR and, in ob/obmice, can lead to a reduction
in liver lipid content (Kammoun et al., 2009). This is attributed to
a decreased expression in SREBP1c and ChREBP, two key tran-
scriptional regulators of lipogenesis. Mice with liver-specific
reduction of IRE1a (IRE1aHepfe/) have minimal phenotypic
changes other than the inability to splice XBP1 into XBP1s and
a reduction in ER content (Zhang et al., 2011a). When these
mice are treated with chemical activators of the UPR (tunicamy-
cin or bortezomib), they develop a greater degree of hepatic
steatosis. These mice display enhanced activation of the other
UPR arms (PERK-eIF2a phosphorylation and ATF6 cleavage).
This is thought to induce key transcriptional regulators of lipo-
genesis such as C/EBPb and d, LXRa and ChREBP, and genes
that promote cellular lipid accumulation (e.g., ACC1, DGAT1,
DGAT2). Tunicamycin treatment of IRE1aHepfe/ mice also
increases expression of adipose differentiation-related protein
[ADRP], a protein that stabilizes lipid droplets, and decreases
hepatic lipid export. Though these changes may be due to
increased activation of PERK and ATF6, it is also possible that
IRE1a may act to suppress lipid accumulation. Thus, loss of
the inhibitory action of IRE1amay allow increased lipid accumu-
lation. Similarly, mice lacking ATF6 a (ATF6a/) are phenotypi-
cally normal but, when challenged with tunicamycin, develop
hepatic steatosis (Yamamoto et al., 2010). This phenotype was
attributed to both decreased expression of genes that regulate
hepatic lipid oxidation and a marked increase in ADRP. These
models demonstrate that deletion of a single arm of the UPR
can lead to increased signaling via the unaffected arms and
also illustrate the intimate relationship between the UPR and
several facets of cellular lipid balance (e.g., lipogenesis, oxida-
tion, etc.).
The PERK arm of the UPR serves to halt protein translation,
essentially by inactivating eukaryotic translation initiation factor
2a (Ron and Walter, 2007). Genetic deletion of PERK causes
severe growth retardation thought to be due to a marked reduc-
tion in hepatic IGF-1 (Li et al., 2003). Interestingly, restoration of
PERK in the b cells alone can provide some degree of rescue;
neonatal mice show similar degrees of growth retardation as
PERK/ but manifest a ‘‘catch-up’’ as juveniles associated
with an increase in plasma IGF-1 concentrations. This resonates
with the other studies demonstrating that activation of the UPR
can be adaptive in the b cells. Currently, there are no reports of
liver- or adipose-specific deletions in PERK. However, liver-
specific inhibition of the PERK pathway has been achieved by
transgenic expression of the C-terminal fragment of GADD34/
PPP1R15a under an albumin promoter (Alb:GC). This gene
encodes a phosphatase that specifically dephosphorylates
eIF2a, effectively terminating the signal from PERK. Alb:GC
mice have reduced body weight and, in contrast to the studies
in IRE1aHepfe/ and ATF6 a/ mice, reduced liver triglyceride
content when challenged with 4 months of high-fat feeding.
This was attributed to an impaired transcriptional induction of
many key genes associated with the development of hepatic
steatosis (e.g., PPARg, FASn, SCD1, etc.) in Alb:GCmice. As ex-
pected, glucose tolerance is improved in these mice.
Alb:GC mice are prone to fasting hypoglycemia and have
decreased expression of gluconeogenic enzymes, the latter
finding attributed to decreased expression of C/EBPa and
b (Oyadomari et al., 2008). Additional metabolic characteriza-
tions were recently performed in these mice after 3 days of
high-fat feeding (Birkenfeld et al., 2011). This short dietary chal-
lenge can specifically result in hepatic triglyceride accumulation
and hepatic insulin resistance without obesity. Whole-body
calorimetry and body composition analysis do not uncover any
differences in energy balance or adiposity in the Alb:GC mice.
The rate of endogenous glucose production is reduced in the
Alb:GC mice, consistent with a reduction in fasting plasma
glucose concentration. However, these studies also yielded
two surprising findings. First, insulin signaling may activate
components of the UPR. Increased Grp78 protein expression
and XBP1s and CHOP mRNA expression is observed in
both wild-type and Alb:GC animals under hyperinsulinemic-
euglycemic conditions, and the increase in XBP1s and CHOP
is enhanced in the Alb:GC mice. Thus, these studies demon-
strate again how impairment of a single UPR arm can lead to
increased activation of other arms. Second, insulin-stimulated
muscle and adipose glucose uptake were actually decreased
in the Alb:GC mice, though neither muscle lipid content nor
adiposity was altered. The development of insulin resistance is
associated with an increase in hepatic insulin-like growth
factor-binding protein 3 (IGFBP3), which itself can impair insulin
action (Yamada et al., 2010). These studies suggest an additional
nuanced role of hepatic UPR: the regulation of peripheral insulin
action through secreted factors by the liver.
The specific role of XBP1s in mediating insulin resistance has
also been tested. Mice lacking one copy of XBP1 (XBP1+/) areprone to glucose intolerance and impaired insulin signaling when
placed on a high-fat diet (Ozcan et al., 2004). Though this is
associated with increased activation of PERK and JNK1, the
XBP+/ mice also gain more weight, a significant confounder.
In contrast, liver-specific deletion of XBP1s (DXBP1s) reduced
hepatic and plasma lipid concentrations in mice, associated
with reduced expression of lipogenic enzymes (Lee et al.,
2008). The reduction in lipogenesis is more evident when the
mice are challenged with a potent lipogenic stimulus such as
a high-fructose diet. Fructose-fed DXBP1s have similar body
weights and fat mass as their wild-type counterparts. However,
DXBP1s mice are protected from the increases in hepatic diac-
ylglycerol and triglyceride content with a reduction in hepatic
PKCε activation (Jurczak et al., 2012). And, as with other models,
there is evidence for activation of other UPR components,
though in this model, this did not lead to hepatic steatosis or
insulin resistance. Taken together, these studies suggest that
the UPR is intricately tied to lipogenesis and that disruption of
any one arm may lead to compensatory increases in signaling
via the other arms. The ability of the UPR to cause hepatic insulin
resistance may ultimately depend on whether UPR activation
alters the balance of lipogenesis and lipid export to promote
hepatic lipid accumulation.
The UPR and Insulin Action in Other Tissues
In adipose tissue, UPR activation appears to regulate energy
balance. Mice with a heterozygous deletion of Grp78
(Grp78+/) had an activation of ‘‘adaptive’’ UPR factors (e.g.,
C/EBP homologous protein [CHOP], XBP1s, and EDEM) and
are protected against diet-induced obesity, hepatic steatosis,
and insulin resistance (Ye et al., 2010). Grp78+/ mice have
increase energy expenditure relative to fat-fed wild-type mice,
which may account for many of the observed changes. The
mechanism for increased energy expenditure is unclear, though
increased adipose expression of peroxisome proliferator
g coactivator 1-a (PGC-1a) raises the possibility of increased
mitochondrial biogenesis. Thus, activation of UPR following
loss of the Grp78 may alter adipogenesis and energy balance
to improve insulin sensitivity. In contrast, in vitro studies in
3T3L1 adipocytes suggest that activation of the UPR may
increase adipose resistin production in a CHOP-dependent
manner (Lefterova et al., 2009) and that the IRE1-XBP1s pathway
is critical for adipogenesis (Sha et al., 2009).
Though the canonical role of the UPR in regulating ER function
has been largely studied in secretory organs, recent studies are
forging a new role for the UPR in skeletal muscle (Figure 2). In
mice, chronic high-fat feeding activates the UPR in both early
(e.g., 6 weeks high-fat feeding) and late stages (20 weeks).
However, 6 weeks of high-fat feeding in healthy human subjects
did not activate the UPR in skeletal muscle, even though there
were the expected changes in glucose tolerance and intramyo-
cellular lipid accumulation. And recently, the UPR has been
shown to interact with PGC-1a in exercising muscle. Specifi-
cally, PGC-1a may coactivate a cassette of genes with ATF6a
to induce adaptive changes to exercise.
It is challenging to combine all of the results of the aforemen-
tioned studies into a simple mechanistic model to explain how
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The models are varied, with different challenges employed (e.g.,
varying diets, chemical inducers) and different assessments of
glucose and insulin action. Reports that chemical chaperones
(e.g., tauroursodeoxycholic acid, TUDCA) improve glucose
homeostasis by alleviating ER stress in rodents (Ozcan et al.,
2006) and humans (Kars et al., 2010) have been used to buttress
the argument that activation of the UPR causes insulin resis-
tance. But these agents can have other confounding effects
such as suppressing mRNA expression of genes involved in de
novo lipogenesis (Yang et al., 2010a) and activating deiodi-
nase-2 (DIO2), which can promote thyroid hormone action
(da-Silva et al., 2011). Thus, it is difficult to conclude that the
UPR directly interferes with insulin signaling and leads to insulin
resistance. Instead, the data suggest that the UPR functions as
a part of integrated cellular response to balance metabolic
needs. Some aspects of the UPR clearly regulate lipogenesis
(e.g., the IRE1a-XBP1s arm), lipid droplet formation, and lipid
storage (e.g., through ATF6) and may also regulate glucose
metabolism (e.g., signaling through eiF2a and CREBH [Lee
et al., 2010; Zhang et al., 2006]). Thus, activation of the UPR
may primarily alter cellular lipid balance and, via accumulation
of lipid intermediates, alter insulin signaling.
Inflammation Integrates a Metabolic Response
Empiric observations demonstrating insulin resistance in septic
patients (Clowes et al., 1978; Iochida et al., 1989; Raymond
et al., 1981; Shangraw et al., 1989) and later chronic elevation
of cytokines in obese and diabetic subjects (Bunout et al.,
1996; Pickup and Crook, 1998; Visser et al., 1999; Yudkin
et al., 2000) suggested that a pathological activation of the innate
immune system may cause insulin resistance and attendant
complications, such as atherosclerosis. Subsequent studies in
obese rodent models of insulin resistance demonstrated an
increase in TNFa in adipose tissue obtained from these animals
(Hotamisligil et al., 1993). TNFa expression was increased in the
adipose tissue obtained from obese subjects, was related to
insulin resistance, and decreased with weight reduction (Hota-
misligil et al., 1995; Kern et al., 1995). Further studies demon-
strate that the defect in insulin signaling can be attributed to
serine phosphorylation of IRS1 at serine-307 residue by activa-
tion of jun-N-terminal kinase 1 (JNK1), providing a plausible
mechanistic link between inflammation and insulin resistance
(Aguirre et al., 2000; Hotamisligil et al., 1996).
Adipose TNFa secretion is now thought to emanate from acti-
vated macrophages (adipose tissue macrophages [ATMs]) that
are recruited via chemokine signaling (Weisberg et al., 2003;
Xu et al., 2003). Adipose tissue overexpression of chemokine
ligand CCL2 (also known as monocyte chemoattractant protein
1 [MCP1]) increases ATMs without any change in body weight
gain or adiposity (Kanda et al., 2006). These mice exhibit both
peripheral and hepatic insulin resistance; the latter is associated
with hepatic steatosis. Consistent with this model, deletion of
CCL2 protects from high-fat diet-induced insulin resistance
and is associated with a reduction in hepatic lipid content (Kanda
et al., 2006). Deletion of theCCL2 receptor, C-Cmotif chemokine
receptor 2 (CCR2), also decreases ATM accumulation and
decreases adiposity and body weight. However, even when
weight-matched animals were compared, loss of CCR2 (as862 Cell 148, March 2, 2012 ª2012 Elsevier Inc.well treatment with a CCR2 antagonist) still conferred metabolic
improvements, as reflected by lower fasting plasma insulin
concentrations and improved glucose tolerance (Weisberg
et al., 2006). These data suggest that recruitment of ATMs is
associated with ectopic lipid accumulation and insulin resis-
tance.
Numerous studies have demonstrated that cytokines increase
adipose lipolysis (Kawakami et al., 1987; Stone et al., 1969), but
the underlying mechanism is unclear. Earlier studies examined
the possibility that cytokines may increase expression of key
lipases. However, TNFa actually decreases expression of
ATLG, which is thought to be secondary to decreased PPARg
expression (Kim et al., 2006; Li et al., 2009). IL-6 infusion in
healthy humans increases plasma fatty acid and glycerol
concentrations (indirect measures of lipolysis). Although adipose
mRNA expression of HSL increased with IL-6, there were no
changes in protein or HSL activity, suggesting that other mech-
anisms are responsible (Watt et al., 2005). Recent studies have
suggested that cytokines may affect the stability of lipid droplets
in adipocytes by influencing the proteins that stabilize the lipid
droplet. TNFa decreases perilipin expression, presumably
enhancing the ability of lipases to access triglyceride within the
lipid droplets (Be´zaire et al., 2009; Laurencikiene et al., 2007).
TNFa, as well as IL-1b and IFNg, has also been shown to
decrease expression of a newly described lipid droplet protein
that is fat-specific protein 27 (FSP27, also known as cell
death-inducing DFFA-like effector c [CIDE C]) (Ranjit et al.,
2011). This protein is homologous to perilipin andmay also serve
to stabilize lipid droplets by controlling lipase access to triglyc-
eride. Silencing of FSP27 enhances basal and TNFa-mediated
lipolysis, whereas overexpression of FSP27 abrogates lipolysis.
Thus, adipose tissue inflammationmay increase lipolysis. This, in
turn, may also contribute to insulin resistance; excess lipolysis
could drive fatty acid re-esterification and ectopic lipid accumu-
lation, leading to the associated impairments in insulin signaling.
But again, there are subtleties to this paradigm. Lipolysis may
also occur with fasting. Calorie restriction in fat-fed mice acutely
increases ATMs and may represent a response to the initial
increase in ATGL-mediated lipolysis (Kosteli et al., 2010). Chem-
ical depletion of ATMs with clodronate increases adipose
lipolysis, suggesting that ATMs may play a role in regulating
the rate of adipose lipolysis. Thus, ATMs may actually meter
lipid release and, in doing so, prevent excess lipid delivery that
would further enhance ectopic lipid accumulation and exacer-
bate insulin resistance. The interaction between macrophages
and adipose tissue may also optimize energy usage in the
organism, permitting lipid release that can be coordinated with
lipid utilization.
ATMs secrete cytokines to orchestrate these metabolic
changes in target tissues through a complex series of signaling
pathways. For example, TNFa binding to the TNF receptor can
lead to activation of the mitogen-activated protein kinase path-
ways (e.g., JNK1, discussed below) as well as the inhibitor of
nuclear factor k-B kinase pathway (IKK), which itself is
composed of three subunits: a (IKK1), b (IKK2), and g (NEMO).
Genetic rodent models provide some insights into how this
pathway may modulate insulin action. Liver-specific deletion of
IKK (i.e., IkbkbDhep) essentially blocks signaling through this
pathway. IkbkbDhep mice are protected from hepatic insulin
resistance and have improved hepatic insulin signaling in both
fat-fed and ob/ob mice though without any improvements in
insulin-stimulated whole-body glucose metabolism (Arkan
et al., 2005). Deletion of IKK-b in myeloid cells (i.e., IkbkbDmye)
confers greater protection from high-fat diet-induced insulin
resistance with improvements in both the liver and muscle
(Arkan et al., 2005). Although these results suggest that
IKK-b activation in myeloid cells may lead to insulin resistance,
IkbkbDmye mice were noted to gain less weight than floxed coun-
terparts (though this difference was not significant). Tissue lipid
content was not assessed in these studies. Instead, the improve-
ments seen in these models were attributed to decreased
expression of key downstream cytokines (e.g., IL-1, IL-6), though
these changes were only associated with a modest decrease in
plasma IL-1b.
Full IKK action requires the regulatory g subunit NF-kB
essential modulator (NEMO). Liver-specific deletion of NEMO
(NEMOL-KO) will prevent IKK activation and suppress signaling
via this pathway. Surprisingly, NEMOL-KO have several hallmarks
of increased inflammation, with increased expression of hepatic
cytokine mRNA (e.g., TNFa and IL-6) and increased activation of
JNK1 (Luedde et al., 2007). When placed on a high-fat diet,
NEMOL-KO mice gain less weight than wild-type counterparts
yet develop marked steatohepatitis. The latter was associated
with a mismatch between the response of PPARa and PPARg
to high-fat feeding. PPARa was not induced, whereas PPARg
had greater induction; the net result is a shift in the transcriptional
regulation that decreases lipid oxidation and favors lipogenesis.
Defying the expectations stemming from increased inflammation
and hepatosteatosis, fat-fed NEMOL-KO have lower fasting
plasma glucose and insulin concentrations and improved
glucose tolerance (Wunderlich et al., 2008). The explanation for
the improvement in glucose metabolism is not entirely clear.
Key lipid intermediates were not assessed. Instead, the improve-
ments were attributed to decreased expression of key gluconeo-
genic enzymes (PEPCK and glucose 6-phosphatase).
NF-kB is the classic IKK target. Phosphorylation of the IkBa
subunit of the NF-kB complex by IKK leads to proteasomal
degradation, allowing nuclear translocation of the p50 and p65
subunits. Overexpression of the p65 subunit will partly simulate
NF-kB activation. Adipose-specific expression of p65 (aP2-p65)
activates adipose-specific inflammation (ATM recruitment,
cytokine production, etc.) but leads to small adipose pads and
protects mice from weight gain when placed on a high-fat diet
(Tang et al., 2010). This is attributed to an increase in energy
expenditure. Accordingly, ap2-p65 transgenic mice are pro-
tected from diet-induced insulin resistance, with improved
hepatic and peripheral insulin sensitivity; the latter was due to
an increase in insulin-stimulated glucose uptake inwhite adipose
tissue (WAT) and heart, but not skeletal muscle. The p50 subunit
can antagonize the effects of p65. Mice lacking p50 (p50-KO)
exhibit a similar phenotype as the aP2-p65 mice, with increased
inflammation, increased energy expenditure, and decreased
adiposity. The Ik-B kinase ε (IKKε) was recently described as
a kinase whose expression is increased by NF-kB activation.
Mice lacking IKKε exhibit a marked upregulation of adipose
UCP1 expression associated with an energy expenditure, withprotection from diet-induced adiposity and insulin resistance
(Chiang et al., 2009).
Activation of inflammatory pathways has been observed as
part of a normal physiological response. In response to acute
aerobic exercise, normal subjects and obese nondiabetic
subjects had an increase in skeletal muscle cytokine expression
(MCP1 and IL-6) as well as activation of the NF-kB pathway
(Tantiwong et al., 2010). Subjects with T2D had high basal NF-
kB activity but did not mount an incremental increase with exer-
cise. The elevations in IL-6, also considered a myokine, may
promotemuscle lipid oxidation. In normal healthymales, infusion
of IL-6 led to increases in both lipolysis and lipid oxidation across
the femoral vascular bed (Wolsk et al., 2010). Although this study
had somemethodological concerns (e.g., lipolysis from subcuta-
neous adipose tissue could have occurred, rates of lipid oxida-
tion are dependent on numerous assumptions, etc.), it does
recapitulate earlier studies demonstrating that IL-6 was capable
of increasing lipid oxidation in isolated rat soleus (Bruce and
Dyck, 2004). As with many of these pathways, physiologically
appropriate regulation is critical. Inappropriate activation of the
IKK/NF-kB pathway, as seen in mice with muscle-specific over-
expression of IKK-b (MIKK mice), can lead to muscle atrophy
(Cai et al., 2004). In the MIKK mice, chronic forced activation
of this pathway leads to increased energy expenditure, which
is associated with increased rates of both protein synthesis
and breakdown. These studies identify the E3 ubiquitin ligase
muscle RING finger protein 1(MuRF1) as a target of NF-kB that
is upregulated in the MIKK mice and may account for the futile
protein cycling that leads to muscle atrophy.
These studies seem to offer discordant conclusions. Some
models in which inflammatory pathways are activated (e.g.,
ap2-p65, p50-KO, MIKK) have increased energy expenditure.
In contrast, deletion of IKKε, which represents a selective block
in inflammatory signaling, also increases energy expenditure.
Resolving these differences on a mechanistic basis is not trivial.
The immune system was intended to coordinate whole-body
responses to various stimuli (Figure 4). Inferring the role of innate
immunity in the development of insulin resistance based on
genetic manipulations of single proteins in specific tissues is
challenging. However, in these disparate models, there is a
consistent axiom. Models with increased energy expenditure
are protected from weight gain, ectopic lipid accumulation,
and insulin resistance. Additional studies will be required to
better delineate the links between innate immunity and energy
balance.
Rethinking the Role of JNK in Insulin Resistance
Despite the multiplicity of intracellular pathways that mediate
the ‘‘inflammatory responses,’’ the explanation for the develop-
ment of insulin resistance in inflammatory states often converges
on the activation of JNK1. Activation of JNK1 also plays a
prominent role in the mechanism whereby the UPR (via IRE1a
activation) may cause insulin resistance. In inflammatory sig-
naling pathways (e.g., in response to TNFa), JNK1 activation
follows a parallel pathway to NF-kB activation. JNK1 knockout
mice are protected from diet-induced insulin resistance.
However, JNK1 knockout mice gain less weight compared to
their wild-type control littermates and had slightly higher bodyCell 148, March 2, 2012 ª2012 Elsevier Inc. 863
Figure 4. Inflammation and Energy Metabolism
Under certain conditions (e.g., adipocyte dysfunction or fasting), the release of
chemokines and/or lipolysis from adipose tissue promotes macrophage
activation. Activated macrophages can then signal to other tissues via the
release of various cytokines (e.g., TFNa, IL-6, etc.). In adipocytes, cytokine
signaling promotes lipolysis via a decrease in lipid droplet stabilizing proteins
(e.g., perilipin or FSP27). In muscle cells, cytokines can promote increase lipid
oxidation and under extreme situations may promote muscle atrophy via
increased proteolysis. In the liver, cytokine signaling may serve to increase
lipogenesis and impair lipid oxidation. The effects on energy balance may
largely depend on the specific cytokines that are activated and the extent of
activation. However, the changes in energy balance may largely dictate the
changes in ectopic lipid accumulation and, ultimately, the development of
insulin resistance.temperatures, implying an increase in energy expenditure
(Hirosumi et al., 2002). These changes are also seen following
JNK1 inactivation in macrophages and adipocytes (via trans-
genic expression of a dominant-negative form of JNK1 under
the aP2 promoter) (Tuncman et al., 2006). These mice have an
increase in energy expenditure and are protected from diet-
induced obesity, hepatic steatosis, and glucose intolerance.
Similar effects are seen in ob/ob mice treated with an ASO
against JNK1. JNK1 ASO treatment increases energy expendi-
ture, possibly via increased BAT expression of UCP1, decreased
body weight gain and liver triglyceride content, decreased
PKCε activation, and improved insulin sensitivity. Thus, as in
the previous models in which intracellular cytokine signaling is
impaired (e.g., IKKε knockout mice), deletion of JNK1 can lead
to increases in energy expenditure, decreased accumulation of
ectopic lipids, and protection from insulin resistance.
Tissue-specific manipulations of JNK1 provide additional
insights. Liver-specific JNK1 deletion actually promotes hepatic
steatosis, associated with increased expression of key lipogenic
enzymes, impaired insulin signaling, and hepatic insulin resis-
tance (Zhang et al., 2011b). Unexpectedly, insulin clearance is
increased, possibly from elevated expression of the insulin864 Cell 148, March 2, 2012 ª2012 Elsevier Inc.receptor and CECAM-1. Similar findings have been observed
with adenoviral-mediated decrease of hepatic JNK1—notably,
an increase in liver lipid production and a decrease in fasting
plasma insulin concentrations (Sabio et al., 2009). Although there
are no published reports of tissue-specific JNK1 activation,
some hints can be gleaned frommice lacking mitogen-activated
kinase phosphatase-1 (MKP1/), a phosphatase that inacti-
vates MAPKs, such as JNK1 (Wu et al., 2006). In MKP1/
mice, JNK1 activity is increased (as is the activity of erk2 and
p38-MAPK), specifically in the nucleus. Despite the increased
JNK1 activity, these chow-fed MKP1/ mice have normal
hepatic insulin sensitivity. In counterpoint to the changes in the
liver-specific JNK1 knockout mice, MKP1/ mice exhibit
evidence of increased lipid oxidation and decreased lipogenesis.
This latter finding may be due to MAPK-mediated inhibition of
PPARg in MKP1/ mice (Flach et al., 2011). These studies
consistently point to a role of JNK1 in regulating hepatocellular
lipid balance, possibly through a combination of inhibiting lipo-
genesis and increased energy expenditure, leading to increased
lipid oxidation.
Additional tissue-specific deletions of JNK1 complete the
variations of this theme. Adipose JNK1 knockout mice are pro-
tected from hepatic steatosis and specifically hepatic insulin
resistance, though they exhibit similar weight gain and adiposity
on a high-fat diet (Sabio et al., 2008). This protection has been
attributed to decreased adipose release of IL-6, which is
thought to impair insulin action via SOCS3. More recently,
muscle-specific JNK1 knockouts have been studied (Sabio
et al., 2010). Fat-fed muscle-specific JNK1 knockout mice
have similar weight gain and impairment of glucose tolerance
as wild-type mice. However, under hyperinsulinemic-euglyce-
mic clamp conditions, they show a modest improvement in
muscle-specific glucose uptake, with improvement in insulin
signaling. Surprisingly, these mice also manifest increased
adipose tissue inflammation and a modest increase in hepatic
steatosis, though without differences in adipose or hepatic
insulin sensitivity.
These studies portray a nuanced role of JNK1 in the pathogen-
esis of insulin resistance, with different effects in different
tissues. Placing the role of JNK1 activation within a comprehen-
sive physiological framework is complicated due to the high
degree of interconnectedness spanning various signaling
networks. For example, JNK1 activation is thought to induce
insulin resistance by serine phosphorylation of IRS1 on a critical
serine 307 residue. However, insulin signaling itself may also
promote phosphorylation of serine 307, independent of the
TNFa-JNK1 pathway (Rui et al., 2001). In contrast, recent studies
suggest that serine 307 phosphorylation may actually augment
insulin action (Copps et al., 2010). Although we can conclude
that alterations in JNK1 activity can alter insulin responsiveness,
its role may be indirect and may instead be related to its ability
to alter intracellular lipid metabolism. Specifically, activation of
JNK1 in adipocytes may increase cytokine release that could
be associated with increased lipolysis. Activation of JNK1 in
hepatocytes (presumably from increased cytokines) may
suppress lipogenesis. This coordinate activation of JNK1 in
key tissues may be part of an orchestrated move to shift meta-
bolic fuel substrates.
Translation to the Bedside
The studies in rodent models are invaluable for understanding
the potential cellular mechanisms for the pathogenesis of insulin
resistance, but are these pathways relevant to humans?
Recently, Kumashiro et al. studied a cohort of obese but nondi-
abetic subjects who were undergoing bariatric surgery and
assessed each of these pathways in flash-frozen liver biopsies
(Kumashiro et al., 2011). Hepatic DAG strongly correlates with
insulin resistance, as assessed by the homeostatic model of
insulin resistance (HOMA-IR) (much better so than body mass
index) and activation of PKCε. Although PKC activation is typi-
cally marked by membrane translocation, plasma membrane
DAG content is weakly correlated with insulin resistance.
Instead, the DAG concentration of a cytoplasmic fraction was
the strongest predictor of insulin resistance in these individuals.
In contrast, hepatic ceramide content did not relate to insulin
resistance. Moreover, there was only a partial activation of the
unfolded protein; specifically, insulin resistance related to
eIF2a phosphorylation and CHOP protein expression, both of
which are downstream of PERK, whereas other aspects of the
UPR did not correlate with insulin resistance, including activation
of JNK1. Finally, there was no relationship between plasma
cytokine concentration (TNFa, IL-1b, IL-6, and CRP) and hepatic
cytokine expression and insulin resistance, suggesting that, in
this cohort of patients, inflammation did not contribute to the
development of insulin resistance.
Teleological and Clinical Implications
In trying to integrate these mechanisms into a single model, it
may be useful to consider the roles that these three pathways
may have played in evolution. After all, these pathways originally
arose to the advantage of the organism, allowing it to adapt to
and thrive in differing environments. The unfolded protein
response may be the most ancient, present in yeast, worm, fly,
and mammals. At the level of individual cells, this pathway may
integrate metabolic signals and adapt accordingly. The innate
immune system may also serve to alter energy metabolism at
the level of whole organisms; in Drosophila, this system can
halt growth to marshal metabolic resources to defend against
a pathogen (DiAngelo et al., 2009). These two systems are highly
interconnected, allowing for a coordinated response to various
environmental stimuli. However, the ability of these systems to
regulate insulin action may be reliant on their ability to alter the
concentration of key lipid signaling intermediates.
These mechanisms that modulate insulin action have
persisted throughout metazoan evolution and presumably con-
ferred a survival advantage. They have been adaptive in environ-
ments of relative nutrient scarcity that require the ability to shift
from glucose to lipid oxidation. Coordinating this metabolic shift
may require the ability to dampen insulin signaling in response to
increased lipid delivery. This can be demonstrated in humans.
Subjects who undergo a prolonged fast become insulin resis-
tant, with reduced insulin-stimulated glucose disposal under
hyperinsulinemic-euglycemic conditions (van der Crabben
et al., 2008). The development of insulin resistance is associated
with increases in plasma fatty acid concentrations, as well as
an accumulation in muscle lipid content. Activation of PKCs is
also associated with starvation-induced insulin resistance inrodents (Hoeks et al., 2010). Thus, it is plausible that the ability
of lipid to trigger insulin resistance may be part of a coordinated
response to preserve glucose for the central nervous system
and vital glucose-obligate organs during starvation.
The cellular mechanisms discussed in this Review are finely
tuned to allow humans to adapt and endure in austerity but
become pathogenic in amodern environment of nutrient excess.
Evidence presented in this Review suggests that ectopic lipid
(diacylglycerols and possibly ceramides) may be at the root
cause of liver and muscle insulin resistance and that new
therapies aimed at decreasing lipid content in these organs will
represent the most efficacious therapeutic targets for the
treatment of insulin resistance and its associated comorbidities.
At a societal level, concerted efforts to restore balance in our
diets and behaviors can prevent obesity and ectopic lipid depo-
sition and can allow these ancient pathways to return to their
physiological role in a healthy life.
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